American Gene Technologies International Inc.
American Gene Technologies International Inc. (“AGT”), is an emerging genetic medicine company with a proprietary lentiviral platform capable of addressing a broad range of large and orphan indications including infectious diseases, immuno-oncology, and monogenic disorders. AGT will submit an IND in 4th quarter 2017 and enter the clinic in early 2018 for a Phase 1 clinical trial to evaluate AGT103 as a functional cure for HIV. Pre-IND applications for phenylketonuria (“PKU”) and hepatocellular carcinoma (“HCC”) will follow. These therapies demonstrate the breadth of AGT’s unique lentiviral platform, including such innovations as a Transient Vector™ for temporary (non-integrating) lentiviral expression and an ImmunoTox™ vector for stimulating anti-tumor immune-response in immuno-oncology applications.
AGT continues to strengthen its patent pipeline and IP protection that now contains ten patent families providing multifactored “picket fence” protection around key developments and technological innovations. AGT’s proprietary platform innovations enable rapid therapeutic discovery at a fraction of the cost of other methods and platforms.
